文献速递白血病

贝林妥欧单抗在可测量残留病阈值10⁻⁴及以上的B细胞系急性淋巴细胞白血病患者中与良好结局相关

Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher.
PubMed 文献 · Am J Hematol · 2022-06-24

这项前瞻性单臂II期研究纳入37例前线治疗≥3个月或挽救治疗1个月后可测量残留病(MRD)≥1×10⁻⁴的成人B细胞急性淋巴细胞白血病患者,给予贝林妥欧单抗标准剂量28微克/日持续输注最多5个周期及最多4个额外维持周期。73%的患者达到MRD阴性缓解,中位随访31个月时估计3年无复发生存率为63%、总生存率为67%。

要点

  • 37例MRD≥1×10⁻⁴的成人B细胞ALL患者接受贝林妥欧单抗治疗,73%达到MRD阴性缓解。
  • 中位随访31个月,估计3年无复发生存率63%(95%CI 43%-77%),总生存率67%(95%CI 46%-81%)。
  • 基线MRD≥1×10⁻³者3年RFS为51%、OS为61%,基线MRD<10⁻³者分别为83%和77%。

核心结论

  • 贝林妥欧单抗使多数患者达到MRD阴性,并带来较高的无复发生存率和总生存率。

研究设计与样本

  • 前瞻性、单臂、II期研究,纳入成人B细胞急性淋巴细胞白血病患者,要求前线治疗开始≥3个月或任何挽救治疗1个月后MRD≥1×10⁻⁴。
  • 共治疗37例患者,中位年龄43岁(范围22-84岁);27例(73%)处于首次完全缓解,10例(27%)处于第二次及以后完全缓解。
  • 贝林妥欧单抗标准剂量为28微克/日持续输注,最多5个周期,并最多4个额外维持周期;中位给药3个周期(范围1-9个周期)。

主要发现

  • 27例(73%)达到MRD阴性缓解。
  • 中位随访31个月(范围5-70个月),估计3年无复发生存率为63%(95%CI 43%-77%),总生存率为67%(95%CI 46%-81%)。
  • 基线MRD≥1×10⁻³的患者3年无复发生存率为51%(95%CI 27%-70%)、总生存率为61%(95%CI 36%-78%)。
  • 基线MRD<10⁻³的患者3年无复发生存率为83%(95%CI 45%-95%)、总生存率为77%(95%CI 32%-95%)。
  • 18例(49%)为费城染色体阳性ALL并接受伴随酪氨酸激酶抑制剂治疗;23例(62%)基线MRD≥10⁻³;不良事件发生率与既往贝林妥欧单抗研究一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The presence of measurable residual disease (MRD) is the strongest predictor of relapse in acute lymphoblastic leukemia (ALL). We conducted a prospective, single-arm, phase II study in adults with B-cell ALL with MRD ≥1 × 10-4 after ≥3 months from the start of frontline therapy or one month from any salvage therapy. Blinatumomab was administered at a standard dosing of 28 micrograms daily as a continuous infusion for up to five cycles and up to four additional maintenance cycles. Thirty-seven patients with a median age of 43 years (range, 22-84 years) were treated. Twenty-seven patients (73%) were treated in first complete remission (CR) and 10 patients (27%) in second CR and beyond. Eighteen patients (49%) had Philadelphia-chromosome positive ALL and received concomitant tyrosine kinase inhibitor therapy. Twenty-three patients (62%) had a baseline MRD ≥10-3 . A median of three cycles (range, 1-9 cycles) were administered. Overall, 27 patients (73%) achieved MRD-negative remission. With a median follow-up of 31 months (range, 5-70 months), the estimated 3-year relapse-free survival (RFS) rate was 63% (95% confidence interval [CI], 43%-77%) and overall survival (OS) rate 67% (95% CI, 46%-81%). These rates were 51% (95% CI, 27%-70%) and 61% (95% CI, 36%-78%) in patients with baseline MRD ≥1 × 10-3 , and 83% (95% CI, 45%-95%) and 77% (95% CI, 32%-95%) in patients with baseline MRD <10-3 respectively. The rates of adverse events were consistent with previous studies of blinatumomab. In summary, blinatumomab induced MRD negativity in most patients and resulted in high rates of RFS and OS. This study is registered at www.clinicaltrials.gov as #NCT02458014. Funding was provided by Amgen Inc.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Jabbour EJ, Short NJ, Jain N, et al. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022. PMID: 35713551. doi:10.1002/ajh.26634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。